)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Curasight
Curasight (CURAS) investor relations material
Curasight Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary31 Aug, 2026
Executive summary
Focus on developing a uPAR-targeted theranostic platform for diagnosis and treatment of aggressive solid tumors, including glioblastoma, NSCLC, and others, with both diagnostic (uTRACE®) and therapeutic (uTREAT®) programs in clinical and preclinical trials.
Achieved key clinical progress with encouraging preliminary Phase 1 data for uTREAT® in glioblastoma, marking a significant milestone for the platform.
Recent internal ownership restructuring consolidated co-founders' holdings under Curacap II ApS, now holding 27.69% of shares, without affecting operations or strategy.
Strengthened financial position through a DKK 20 million directed share issue and extension of a DKK 35 million convertible loan to mid-2027, supporting ongoing clinical programs.
Updated clinical timelines: topline Phase I uTREAT® in glioblastoma and Phase II uTRACE® in prostate cancer expected H1 2027.
Financial highlights
H1 2026 gross loss: KDKK -22,875 (vs. KDKK -22,399 year-over-year); operating loss: KDKK -26,771 (vs. KDKK -25,220); loss before tax: KDKK -29,505 (vs. KDKK -27,158); net loss: KDKK -26,755 (vs. KDKK -24,408).
Q2 2026 gross loss: KDKK -9,797 (vs. KDKK -17,700); operating loss: KDKK -11,493 (vs. KDKK -19,011); loss before tax: KDKK -12,800 (vs. KDKK -20,579); net loss: KDKK -11,425 (vs. KDKK -19,204).
Total assets: KDKK 56,081 (vs. KDKK 44,783); equity ratio: 27.1% (vs. 67.6%); EPS: DKK -0.24 (vs. DKK -0.43).
Cash in hand as of June 30, 2026: KDKK 41,026 (vs. KDKK 29,449 year-over-year).
Short-term debt: KDKK 40,868, mainly from a drawn credit facility.
Outlook and guidance
Topline results for Phase I uTREAT® in glioblastoma and Phase II uTRACE® in prostate cancer expected H1 2027, with timelines reflecting patient enrollment uncertainties.
Protocol amendment in Phase I uTREAT® trial aims to optimize study design and broaden data for next phase.
Regulatory tailwind anticipated for glioblastoma program.
Continued disciplined execution and robust clinical evidence generation are strategic priorities.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Curasight
- uTREAT trials in brain cancer begin 2025, with strong funding and major partnership milestones ahead.CURAS
Status update - Losses widened in Q1 2026, but clinical and financial progress set up key 2026 milestones.CURASQ1 2026
- Losses increased but cash and equity improved, with major clinical and financing milestones achieved.CURASQ4 2025
- Advanced clinical pipeline and strong cash position despite higher losses year-over-year.CURASQ3 2025
- Financials strengthened and clinical trials advanced in prostate and brain cancer.CURASQ2 2025
- Curasight achieved major clinical and financing milestones, strengthening its position in radiopharma.CURASQ3 2024
- Losses widened but new funding and clinical milestones support growth into 2025.CURASQ2 2024
- DKK 100 million rights issue to fund pivotal cancer trials, with 47% secured by commitments.CURASInvestor update
- Rights issue targets DKK 100 million to fund key cancer platform trials and extend cash runway.CURASInvestor update
Next Curasight earnings date
Q3 202626 Nov, 2026
Curasight
Next Curasight earnings date
Q3 202626 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Curasight is a clinical stage biopharmaceutical company dedicated to developing uPAR Theranostics for the early detection, diagnosis and treatment of cancer. The company's mission is to make a global impact by harnessing imaging technology that improves diagnosis and correlates to improved long-term patient outcome.